PROMIS physical and mental health measures are responsive to DMARD therapy in rheumatoid arthritis

被引：0
|
作者：
Bingham, Clifton [1 ]
Wohlfahrt, Alyssa [2 ]
Marder, Wendy [3 ]
Neogi, Tuhina [4 ]
Bolster, Marcy [5 ]
Phillips, Kristine [6 ]
Lee, Yvonne [7 ]
机构：
[1] Johns Hopkins, Baltimore, MD USA
[2] Brigham & Womens, Boston, MA USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Boston Univ, Boston, MA 02215 USA
[5] Massachusetts Gen, Boston, MA USA
[6] Vanderbilt, Nashville, TN USA
[7] Northwestern, Chicago, IL USA
来源：
QUALITY OF LIFE RESEARCH | 2018年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
3032
引用
收藏
页码：S177 / S178
页数：2
相关论文
共 50 条
  • [41] Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?
    Carlo A. Marra
    Amir A. Rashidi
    Daphne Guh
    Jacek A. Kopec
    Michal Abrahamowicz
    John M. Esdaile
    John E. Brazier
    Paul R. Fortin
    Aslam H. Anis
    [J]. Quality of Life Research, 2005, 14 : 1333 - 1344
  • [42] Calibration of the PROMIS Physical Function Item Bank in Dutch Patients with Rheumatoid Arthritis
    Voshaar, Martijn A. H. Oude
    ten Klooster, Peter M.
    Glas, Cees A. W.
    Vonkeman, Harald E.
    Taal, Erik
    Krishnan, Eswar
    Moens, Hein J. Bernelot
    Boers, Maarten
    Terwee, Caroline B.
    van Riel, Piet L. C. M.
    van de laar, Mart A. F. J.
    [J]. PLOS ONE, 2014, 9 (03):
  • [43] Outcome of a patient with rheumatoid arthritis treated with homeopathic drugs without DMARD therapy
    Keysser, Gernot
    [J]. MEDIZINISCHE KLINIK, 2008, 103 (01) : 36 - 37
  • [44] Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users
    Nasir Wabe
    Anita Lee
    Mihir Wechalekar
    Leah McWilliams
    Susanna Proudman
    Michael Wiese
    [J]. Rheumatology International, 2017, 37 : 897 - 904
  • [45] Atlantoaxial subluxation can be prevented by combination DMARD therapy in early rheumatoid arthritis
    Neva, MH
    Kauppi, M
    Kauttainen, H
    Hannonen, P
    Leirisalo-Repo, M
    Nissila, M
    Mottonen, T
    [J]. ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S80 - S80
  • [46] JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy
    Vaddi, Kris
    Luchi, Monica
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (07) : 961 - 973
  • [47] Contribution of leflunomide to the cost effectiveness sequential DMARD therapy of rheumatoid arthritis in Germany
    Lakomek, HJ
    Roeder, N
    Liman, W
    Gross, WL
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2004, 63 (01): : 59 - 60
  • [48] Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany
    Schädlich, PK
    Zeidler, H
    Zink, A
    Gromnica-Ihle, E
    Schneider, M
    Straub, C
    Brecht, JG
    Huppertz, E
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2004, 63 (01): : 61 - 77
  • [49] FACTORS CONTRIBUTING TO DELAY IN USE OF DMARD THERAPY IN EARLY RHEUMATOID ARTHRITIS PATIENTS
    Raczkiewicz, A.
    Juszkiewicz, A.
    Bachta, A.
    Bujakowska, O.
    Kur-Zalewska, J.
    Kisiel, B.
    Ttustochowicz, M.
    Tiustochowicz, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 968 - 969
  • [50] DOES THE PRESENCE OF ILD INFLUENCE THE CHOICE OF DMARD AND BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS?
    Coath, F.
    Siddiqui, S.
    Himashi, A.
    Bharadwaj, A.
    Dubey, S.
    Hayes, F.
    Koduri, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1345 - 1345
12345